Status: Recruiting
TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System
This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.
Participants needed: 150
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Cardiovalve Ltd.Updated: May 11, 2026Locations: 1
Eligibility criteria
Subject is ≥ 18 and <85 years [+10]
Cardiac anatomy deemed not suitable for the Cardiovalve TR system as evaluated (... [+29]